US20110038848A1 - Dietary supplement compositions for cardiovascular health - Google Patents
Dietary supplement compositions for cardiovascular health Download PDFInfo
- Publication number
- US20110038848A1 US20110038848A1 US12/854,944 US85494410A US2011038848A1 US 20110038848 A1 US20110038848 A1 US 20110038848A1 US 85494410 A US85494410 A US 85494410A US 2011038848 A1 US2011038848 A1 US 2011038848A1
- Authority
- US
- United States
- Prior art keywords
- ester
- composition
- contain
- coenzyme
- dietary supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title abstract description 88
- 230000036996 cardiovascular health Effects 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 17
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 52
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 35
- 235000019136 lipoic acid Nutrition 0.000 claims description 33
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 33
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 33
- 229960002663 thioctic acid Drugs 0.000 claims description 33
- 239000006014 omega-3 oil Substances 0.000 claims description 27
- 229940068065 phytosterols Drugs 0.000 claims description 21
- 108010004032 Bromelains Proteins 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 14
- 235000019835 bromelain Nutrition 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 35
- 235000012000 cholesterol Nutrition 0.000 abstract description 12
- 239000004615 ingredient Substances 0.000 abstract description 5
- -1 sterol compound Chemical class 0.000 description 70
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 28
- 229930182558 Sterol Natural products 0.000 description 27
- 235000003702 sterols Nutrition 0.000 description 27
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 25
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 25
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 25
- 150000002148 esters Chemical class 0.000 description 16
- 235000021323 fish oil Nutrition 0.000 description 16
- 239000003826 tablet Substances 0.000 description 15
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 14
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 14
- 239000002775 capsule Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 13
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 13
- 229940110767 coenzyme Q10 Drugs 0.000 description 13
- 235000017471 coenzyme Q10 Nutrition 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 229940066675 ricinoleate Drugs 0.000 description 11
- 150000003432 sterols Chemical class 0.000 description 11
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 description 9
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 9
- 235000000431 campesterol Nutrition 0.000 description 9
- 229940070765 laurate Drugs 0.000 description 9
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 229940049964 oleate Drugs 0.000 description 8
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 7
- KZJWDPNRJALLNS-FBZNIEFRSA-N Clionasterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 7
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229940075999 phytosterol ester Drugs 0.000 description 7
- 229940032091 stigmasterol Drugs 0.000 description 7
- 235000016831 stigmasterol Nutrition 0.000 description 7
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 229940049918 linoleate Drugs 0.000 description 6
- 239000007845 reactive nitrogen species Substances 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 5
- KZJWDPNRJALLNS-STIDJNKJSA-N gamma-sitosterol Natural products CC[C@@H](CC[C@@H](C)[C@@H]1CC[C@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C KZJWDPNRJALLNS-STIDJNKJSA-N 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 5
- 150000001733 carboxylic acid esters Chemical class 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000828 canola oil Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229940013317 fish oils Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- LPZCCMIISIBREI-JXMPMKKESA-N (Z)-24-ethylidenelophenol Chemical compound C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC/C(=C/C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 LPZCCMIISIBREI-JXMPMKKESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001597725 Callobius canada Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940019897 coenzyme Q10 30 mg Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000010497 wheat germ oil Substances 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MWBFEMKEWAGWSZ-UHFFFAOYSA-N O=C(O)CCCCC(S)CCS.O=C(O)CCCCC1CCSS1 Chemical compound O=C(O)CCCCC(S)CCS.O=C(O)CCCCC1CCSS1 MWBFEMKEWAGWSZ-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- QRXQVKMPSJDAKS-UHFFFAOYSA-N [H]C/C(C)=C/CC1=C(C)C(=O)C(CO)=C(CO)C1=O.[H]C/C(C)=C/CC1=C(C)C(O)=C(CO)C(CO)=C1O Chemical compound [H]C/C(C)=C/CC1=C(C)C(=O)C(CO)=C(CO)C1=O.[H]C/C(C)=C/CC1=C(C)C(O)=C(CO)C(CO)=C1O QRXQVKMPSJDAKS-UHFFFAOYSA-N 0.000 description 1
- FAOPQARMGHSCIV-IWQLHOTHSA-N [H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1([H])[C@H](C)CC[C@@H](CC)C(C)C.[H][C@@]12CCC3=C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1([H])[C@H](C)CCCC(C)C Chemical compound [H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1([H])[C@H](C)CC[C@@H](CC)C(C)C.[H][C@@]12CCC3=C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1([H])[C@H](C)CCCC(C)C FAOPQARMGHSCIV-IWQLHOTHSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- IWTJDVBNIUPPPB-FPNUYMRSSA-N beta-Sitosterol palmitate Natural products C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 IWTJDVBNIUPPPB-FPNUYMRSSA-N 0.000 description 1
- IWTJDVBNIUPPPB-UHFFFAOYSA-N beta-Sitosterylpalmitat Natural products C12CCC3(C)C(C(C)CCC(CC)C(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 IWTJDVBNIUPPPB-UHFFFAOYSA-N 0.000 description 1
- TXNOTJVZNDGTOR-QXKOIZLYSA-N beta-sitosteryl linoleate Natural products CCCCCC=C/CC=C/CCCCCCCC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CC=C2C1)[C@H](C)CC[C@@H](CC)C(C)C TXNOTJVZNDGTOR-QXKOIZLYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- SCIGVHCNNXTQDB-UHFFFAOYSA-N decyl dihydrogen phosphate Chemical compound CCCCCCCCCCOP(O)(O)=O SCIGVHCNNXTQDB-UHFFFAOYSA-N 0.000 description 1
- DZQISOJKASMITI-UHFFFAOYSA-N decyl-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound CCCCCCCCCCP(O)(O)=O DZQISOJKASMITI-UHFFFAOYSA-N 0.000 description 1
- OESHPIGALOBJLM-REOHCLBHSA-N dehydroascorbate Chemical compound OC[C@H](O)[C-]1OC(=O)C(=O)C1=O OESHPIGALOBJLM-REOHCLBHSA-N 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- PDTRBCTYOYMYKK-RFIDALOWSA-N diethyl (2r,3r)-2,3-dihydroxybutanedioate;(2r,3r)-2,3-diethyl-2,3-dihydroxybutanedioic acid Chemical compound CCOC(=O)[C@H](O)[C@@H](O)C(=O)OCC.CC[C@](O)(C(O)=O)[C@](O)(CC)C(O)=O PDTRBCTYOYMYKK-RFIDALOWSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HTDKEJXHILZNPP-UHFFFAOYSA-N dioctyl hydrogen phosphate Chemical compound CCCCCCCCOP(O)(=O)OCCCCCCCC HTDKEJXHILZNPP-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- TVACALAUIQMRDF-UHFFFAOYSA-N dodecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(O)=O TVACALAUIQMRDF-UHFFFAOYSA-N 0.000 description 1
- SVMUEEINWGBIPD-UHFFFAOYSA-N dodecylphosphonic acid Chemical compound CCCCCCCCCCCCP(O)(O)=O SVMUEEINWGBIPD-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- ZKAAVBQKARRBFN-UHFFFAOYSA-N lauric acid beta-sitostenol ester Natural products C12CCC3(C)C(C(C)CCC(CC)C(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCC)C2 ZKAAVBQKARRBFN-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This document relates to the field of dietary supplements.
- this document relates to composition having a combination of ingredients useful in reducing cholesterol and improving overall cardiovascular health.
- CVD Cardiovascular disease
- statin drugs such as lovastatin, pravastatin, and simavastatin to reduce cholesterol levels
- the impact of these prescription medications on the heart, liver, and muscles have raised safety concerns.
- statins is mainly focused on reducing serum cholesterol levels, while CVD has multiple pathological mechanisms.
- Atherosclerosis a process of accumulating plaques in major blood vessels. This disease is very hard to treat and almost impossible to reverse, but it is highly preventable. There are few risk factors responsible for atherosclerosis progression. One of the most important is high blood cholesterol. According to modern research the mechanism of arterial plaque formation includes free radical oxidation of LDL, the major cholesterol transporting complex in the blood. Another important aspect of atherosclerosis development is inflammation. Increased inflammatory background is not just a risk factor, it is an indicator of active plaque formation processes. Thus, a high level of inflammatory markers in the blood is believed to be a better predictor of cardiac events than high cholesterol.
- This document provides dietary supplements.
- this document provides composition having a combination of ingredients useful in reducing cholesterol and improving overall cardiovascular health as well as methods for reducing cholesterol and improving overall cardiovascular health.
- a dietary supplement comprising, or consisting essentially of, (a) from about 400 mg to about 3000 mg phytosterols, (b) from about 110 mg to about 1000 mg omega-3 fatty acids, (c) from about 6 mg to about 60 mg coenzyme Q-10, (d) from about 6 mg to about 45 mg alpha lipoic acid, and (e) from about 2.5 mg to about 20 mg bromelain.
- the dietary supplement can comprise, or consist essentially of, (a) from about 1400 mg to about 2800 mg phytosterols, (b) from about 300 mg to about 800 mg omega-3 fatty acids, (c) from about 20 mg to about 40 mg coenzyme Q-10, (d) from about 20 mg to about 36 mg alpha lipoic acid, and (e) from about 8 mg to about 15 mg bromelain.
- the dietary supplement can comprise, or consist essentially of, (a) about 2000 mg phytosterols, (b) about 550 mg omega-3 fatty acids, (c) about 30 mg coenzyme Q-10, and (d) about 30 mg alpha lipoic acid.
- a dietary supplement can comprise, or consist essentially of, (a) about 500 mg phytosterols; (b) about 250 mg omega-3 fatty acids; (c) about 7.5 mg coenzyme Q-10; and (d) about 7.5 mg alpha lipoic acid.
- a dietary supplement can comprise, or consist essentially of, (a) from about 1000 mg to about 3000 mg phytosterols; (b) from about 500 mg to about 1500 mg omega-3 fatty acids; (c) from about 15 mg to about 45 mg coenzyme Q-10; (d) from about 15 mg to about 45 mg alpha lipoic acid; and (e) from about 2.5 mg to about 20 mg bromelain.
- the method can include administering to the mammal a daily dosage of a dietary supplement, wherein the dietary supplement can include: (a) from about 1000 mg to about 3000 mg phytosterols; (b) from about 500 mg to about 1500 mg omega-3 fatty acids; (c) from about 15 mg to about 45 mg coenzyme Q-10; (d) from about 15 mg to about 45 mg alpha lipoic acid; and (e) from about 2.5 mg to about 20 mg bromelain.
- a daily dosage of a dietary supplement can include: (a) from about 1000 mg to about 3000 mg phytosterols; (b) from about 500 mg to about 1500 mg omega-3 fatty acids; (c) from about 15 mg to about 45 mg coenzyme Q-10; (d) from about 15 mg to about 45 mg alpha lipoic acid; and (e) from about 2.5 mg to about 20 mg bromelain.
- This document provides methods and compositions related to lowering blood cholesterol, reducing the inflammation background, and increasing the antioxidant potential of the blood.
- the methods and compositions are believed to slow down atherosclerosis development and lower the risk of cardiac events.
- the methods and compositions are believed to provide a variety of health benefits, including: helping reduce the risk of heart disease, helping support heart and blood vessel function, naturally helping reduce cholesterol levels for a healthier heart and life, supporting blood circulation, adding coenzyme Q-10 to offset reduced amounts during aging, and helping to regenerate antioxidants.
- compositions e.g. dietary supplements
- a sterol compound e.g. a sterol compound
- omega-3 fatty acids EPA/DHA
- coenzyme Q10 a sterol compound
- ⁇ -lipoic acid e.g. a sterol compound
- EPA/DHA omega-3 fatty acids
- a daily dose of a dietary supplement as provided herein.
- the dietary supplement can be formulated with amounts as provided herein.
- Administration can be provided as one or more compositions (e.g., tablets).
- compositions provided herein can contain a sterol compound such as a phytosterol compound.
- the sterol can be synthetic.
- the term “sterol” includes, without limitation, plant, animal, and synthetic sterols, sterol esters, stanols, and stanol esters. Plant sterols (and sterol esters) are naturally occurring substances present in the diet as minor components of vegetable oils, while plant stanols (and stanol esters) are hydrogenation compounds of the plant sterols.
- the cholesterol lowering effect of sterols is thought to be associated with their structural similarity.
- Sterols may compete with cholesterol for places in micelles—small fat particles which form during digestion in order to adsorb fat. Because of this, sterols may prevent absorption and re-absorption of cholesterol from the intestinal tract and thus can affect blood cholesterol levels.
- Sterols have been approved for safe use by the FDA and they have been safely used in studies lasting up to 18 months. A significant number of research studies have shown that sterols can reduce total cholesterol and LDL cholesterol levels.
- Sterol compounds e.g., phytosterols and phytosterol esters
- sterol compounds can be synthesized and/or obtained from natural sources such as soy oil, canola oil, or wheat germ oil as described elsewhere (see e.g. U.S. Pat. Nos. 6,411,206; 5,502,045; 6,087,353; and 4,897,224, each of which is incorporated herein by reference in its entirety).
- phytosterol esters that can be used to prepare a composition provided herein include, without limitation, beta-sitosterol laurate ester, alpha-sitosterol laurate ester, gamma-sitosterol laurate ester, campesterol myristearate ester, stigmasterol oleate ester, campesterol stearate ester, beta-sitosterol oleate ester, beta-sitosterol palmitate ester, beta-sitosterol linoleate ester, alpha-sitosterol oleate ester, gamma-sitosterol myristearate ester, beta-sitosterol ricinoleate ester, campesterol laurate ester, campesterol ricinoleate ester, campesterol oleate ester, campesterol linoleate ester, stigmasterol lino
- a sterol compound can be a phytostanol ester.
- Sterol compounds such as phytostanols and phytostanol esters can be obtained commercially from, e.g., Forbes Meditech (Vancouver, B.C. Canada), or can be readily synthesized.
- phytostanols and phytostanol esters can be obtained from natural sources such as soy oil, canola oil, or wheat germ oil as described elsewhere (see e.g. U.S. Pat. Nos. 6,411,206; 5,502,045; 6,087,353; and 4,897,224).
- phytostanol esters that can be used to make a composition provided herein include, without limitation, beta-sitostanol laurate ester, campestanol myristearate ester, stigmastanol oleate ester, campestanol stearate ester, beta-sitostanol oleate ester, beta-sitostanol palmitate ester, beta-sitostanol linoleate ester, beta-sitostanol myristearate ester, beta-sitostanol ricinoleate ester, campestanol laurate ester, campestanol ricinoleate ester, campestanol oleate ester, campestanol linoleate ester, stigmastanol linoleate ester, stigmastanol laurate ester, stigmastanol caprate ester, stigmastanol stearate ester, alpha-sitostano
- a composition provided herein can contain any type of sterol compound such as a phytosterol, phytosterol ester, phytostanol, or phytostanol ester.
- a composition provided herein can contain any amount of sterol compounds (e.g., 10, 25, 50, 100, 200, 250, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 750, 800, or 900 mg).
- compositions provided herein can contain sterol compounds.
- a composition provided herein can be designed to contain multiple sterol compounds in any relative ratio (e.g., 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1).
- a composition provided herein can be a nutritional supplement with a label indicating that a suggested serving size includes greater than 1 g (e.g., about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 3.0, 3.5 g or more) of total sterol compounds per day.
- 1 g e.g., about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 3.0, 3.5 g or more
- a composition provided herein can be designed to contain a phytosterol ester compound or mixtures thereof.
- a composition provided herein can be designed to contain one or more phytosterol ester compounds in a total amount ranging from about 45% to about 95% by weight of the composition.
- one or more phytosterol ester compounds can be provided in a total amount from about 45% to about 60% by weight of the composition.
- one or more phytosterol ester compounds can be provided in a total amount of about 70% to about 85% by weight of the composition.
- a composition provided herein can contain one or more phytosterol compounds.
- one or more phytosterols can be present in a total amount from about 1% to about 85% by weight of the composition.
- one or more phytosterol compounds may be present in a total amount from about 1% to about 10% by weight of the composition.
- one or more phytosterols can be present in a total amount of from about 40% to about 55%, or from about 70% to about 85% by weight of the composition.
- a composition provided herein can contain one or more phytostanol ester compounds, e.g., in a total amount of from about 45% to about 95% by weight of the composition. In certain embodiments, one or more phytostanol ester compounds can be provided in a total amount of about 45% to about 60% by weight of the composition. In other embodiments, one or more phytostanol ester compounds can be provided in a total amount of about 70% to about 85% by weight of the composition.
- one or more phytostanol compounds can be present in a total amount from about 1% to about 85% by weight of the composition. In other compositions, one or more phytostanols can be present in a total amount of from about 1% to about 10%, from about 40% to about 55%, or from about 70% to about 85% by weight of the composition.
- compositions provided herein can contain one or more fatty acid compounds (e.g., ⁇ -3 fatty acid compounds).
- Omega-3 fatty acids stimulate blood circulation, increase the breakdown of fibrin, a compound involved in clot and scar formation, and additionally have been shown to reduce blood pressure.
- ⁇ -3 fatty acids reduce blood triglyceride levels and regular intake reduces the risk of secondary and primary heart attack.
- omega-3 fatty acids Two common forms of omega-3 fatty acids are can generally be in a form generally known as eicosapentanoic acid (EPA) and derivatives thereof and docosahexanoic acid (DHA) and derivatives thereof.
- EPA eicosapentanoic acid
- DHA docosahexanoic acid
- Fatty acid compounds such as ⁇ -3 fatty acid compounds can be obtained from fish oils or vegetable oils, or synthesized.
- fatty acid compounds such as ⁇ -3 fatty acid compounds can be formulated in a composition as a fish oil or vegetable oil or mixture thereof.
- a fish oil containing DHA, EPA, or both can be used to make a composition provided herein.
- Fish oils are available commercially from BLT Berg Lipidtech AS, Clover Corporation, Denofa AS, Bioriginal Food and Science Corp., ProNova Biocare, BASF, and NutriScience Innovations LLC, and can demonstrate a range of ⁇ -3 fatty acid profiles.
- a fish oil can contain about 11-14% DHA and about 16-19% EPA, and a total ⁇ -3 fatty acid content of about 33-41%.
- a fish oil can contain about 12% DHA and about 18% EPA.
- a fish oil can contain about 30-33% EPA and about 20-22% DHA, and a total ⁇ -3 fatty acid content of about 50-67%.
- a fish oil can contain about 50-55% DHA and about 5-10% EPA.
- a fish oil can contain about 50-55% EPA and about 5-10% DHA.
- a fish oil can contain at least 20% DHA and at least 25% EPA, and a total ⁇ -3 fatty acid content of at least 60%, e.g., at least 65%. In yet other cases, a fish oil can contain about 5% EPA and about 25% DHA, and a total ⁇ -3 fatty acid content of about 30%, e.g., about 35%.
- a fish oil containing EPA and/or DHA (or derivatives thereof) can be modified by, e.g., the addition of purified EPA and/or DHA (or derivatives thereof) to result in a particular ratio or amount of EPA and/or DHA (or derivatives thereof).
- purified EPA and/or DHA, or derivatives thereof can be used to make a composition provided herein.
- a ratio of EPA to DHA, or derivatives thereof can be from about 1:5 to about 5:1, or from about 1:2 to about 2:1, or from about 1.5:1 to about 1:1.5.
- a fish oil can contain EPA and DHA at a ratio of about 1.5:1.
- a composition provided herein can contain a fish oil in a range of from about 10% to about 55% by weight of the composition, or from about 10% to about 30% by weight of the composition.
- EPA and/or DHA, or derivatives thereof can be used in purified form to make a composition provided herein.
- the combined amount of EPA and DHA (or derivatives thereof) can range from about 30% to about 55% by weight of the composition.
- the combined amount of EPA and DHA can range from about 20% to about 40% by weight of the composition.
- the combined amount of EPA and DHA can range from about 12% to about 16% by weight of the composition.
- Fish oils, purified EPA, DHA, and derivatives thereof such as DHA and EPA can be obtained commercially from, for example, Croda, Inc. (Parsippany, N.J.), Roche Vitamins Ltd. (Parsippany, N.J.), Martek (Boulder, Colo.), Maritex (Sortland, Norway), Seven Seas, Pronova (Lysker, Norway), and Loder Croklann Lipid Nutrition (Channahon, Ill.), and Cargill, Inc. (Minneapolis, Minn.).
- a composition provided herein can be a nutritional supplement.
- a nutritional supplement can include a label indicating that a suggested serving size includes at least 300 mg (e.g., about 300, 350, 400, 420, 450, 500, 500-600, 600-900, 1000, 1100, 1200, 900-1200, 1200-1500 mg, 1500 mg-2 g, 2 g-2.5 g, 2.5 g-3 g, or more) of total ⁇ -3 fatty acids per day.
- One or more ⁇ -3 fatty acids can be derived from one or more fish, purified ⁇ -3 fatty acids, or mixtures thereof.
- a nutritional supplement can include a label indicating that a suggested serving size includes at least 300 mg of DHA and EPA per day.
- compositions provided herein can contain Coenzyme Q-10.
- Coenzyme Q-10 also referred to herein as CoQ10
- All risk groups should preferably maintain a healthy blood level of CoQ10. This is important for people who are on statin (inhibitors of cholesterol biosynthesis) therapy.
- Coenzyme Q10 (CoQ10) is produced by the human body and is necessary for the basic functioning of cells. CoQ10 plays a key role in producing energy in the mitochondria, the part of a cell responsible for the production of energy in the form of ATP. It does so through the conversion of oxidized and reduced forms (ubiquinone-ubiquinol) of the coenzyme.
- CoQ10 levels are reported to decrease with age and to be low in patients with some chronic diseases such as heart conditions, muscular dystrophies, Parkinson's disease, cancer, diabetes, and HIV/AIDS. People with heart failure have been found to have lower levels of CoQ10 in heart muscle cells. Some prescription drugs may also lower CoQ10 levels.
- CoQ10 (in appropriate form) is relatively bioavailable.
- the average plasma level in human is about 0.7-0.9 ⁇ g/mL. Desirable levels for people with elevated risk of heart disease is more than 1 ⁇ g/mL. Supplementation may increase the plasma level very quickly.
- CoQ10 can be included in an amount ranging from about 0.01% to about 2% by weight of the composition, or from about 0.1% to about 1% by weight.
- compositions provided herein can contain ⁇ -Lipoic acid (LA), also known as thioctic acid, LA is an essential cofactor for several important enzyme complexes, it can directly scavenge (neutralize) physiologically relevant Reactive Oxygen and Nitrogen Species (ROS and RNS), it also can directly or indirectly regenerate the oxidized forms of other antioxidants such as Ascorbic acid, ⁇ -Tocopherol, and CoQ10.
- LA ⁇ -Lipoic acid
- ROS and RNS Reactive Oxygen and Nitrogen Species
- LA is a naturally occurring compound that is synthesized in small amounts by plants and animals, including humans.
- LA contains two thiol (sulfur) groups.
- the reduced form is known as dihydrolipoic acid (DHLA), while the oxidized form is known as LA.
- DHLA dihydrolipoic acid
- ROS Reactive oxygen species
- RNS reactive nitrogen species
- ROS reactive oxygen species
- RNS reactive nitrogen species
- Both LA and DHLA can directly scavenge (neutralize) physiologically relevant ROS and RNS in the test tube.
- LA acts directly to scavenge ROS and RNS in vivo.
- an antioxidant scavenges a free radical, it becomes oxidized itself and is not able to scavenge additional ROS or RNS until it has been reduced.
- DHLA is a potent reducing agent with the capacity to reduce the oxidized forms of several important antioxidants, including vitamin C and glutathione.
- DHLA may also reduce the oxidized form of alpha-tocopherol (the alpha-tocopheroxyl radical) directly or indirectly, by reducing the oxidized form of vitamin C (dehydroascorbate), which is able to reduce the alpha-tocopheroxyl radical.
- Coenzyme Q10 is an important component of the mitochondrial electron transport chain that also has antioxidant activity.
- DHLA can also reduce oxidized forms of coenzyme Q10, which may also reduce the alpha-tocopheroxyl radical.
- LA has multiple health benefits. Glutathione is an important intracellular antioxidant that also plays a role in the detoxification and elimination of potential carcinogens and toxins. LA has been found to increase glutathione synthesis in cultured cells and in the tissues of aged animals fed LA.
- compositions provided herein can contain bromelain.
- the bromelain is provided in an amount ranging from about 0.1% to about 5% by weight of the composition, or from about 0.5% to about 2.5% by weight of the composition.
- Bromelain is the generic name for a family of sulfhydryl-containing proteolytic enzymes obtained from the pineapple plant.
- a bromelain enzyme blend generally contains a sulfydryl proteolytic fraction, a peroxidase, an acid phosphatase, several protease inhibitors, and calcium.
- compositions that can include one or more of: sterols, omega-3 fatty acids, coenzyme Q-10, and alpha lipoic acid.
- a dietary supplement composition provided herein can contain the amounts indicated in Table 1 below.
- a dietary supplement composition provided herein can contain the amounts indicated in Table 2 below.
- a daily dosage of the dietary supplement composition can contain the following:
- a daily dosage of the dietary supplement composition can contain the following:
- a daily dosage of the dietary supplement composition can contain the following:
- a daily dose refers to the amount of active ingredient administered over a 24 hour period.
- a daily dose may be prepared and administered in the form of one or more tablets (e.g., two tablets, three tablets, four tablets, five tablets, and six tablets).
- the one or more tablets can be administered in one or more dosages over the course of 24 hours (e.g., one dose, two doses, three doses, four doses, five doses, and six doses), wherein the one or more dosages do not exceed the total daily dose.
- the tablet when a daily dose is prepared for administration as a single tablet per day, the tablet can contain the following:
- each tablet can contain the following:
- each tablet can contain the following:
- compositions described herein can contain additional optional ingredients.
- optional coloring and/or flavoring agents e.g., to reduce the odor associated with fish oil and fish oil components
- the compositions can contain a pharmaceutically acceptable carrier for in vivo administration to a mammal, including, without limitation, preservatives and other additives such as, for example, botanical extracts.
- compositions provided herein can be formulated as nutritional supplements, e.g., as liquids or capsules for oral ingestion.
- Capsules can be hard-shell or soft gel capsules.
- compositions provided herein can be ingested (e.g., orally or intragastrically).
- the route of administration can depend on a variety of factors, such as the health of the patient and the therapeutic goals.
- One method of administration is orally in the form of capsules at daily-recommended dosages.
- Capsules are provided in sizes that are acceptable for the consumer to swallow.
- capsules can be in the range from about 250 mg to 3 g in size, or any size therebetween (e.g., 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, 475 mg, 490 mg, 500 mg, 550 mg, 575 mg, 600 mg, 650 mg, 675 mg, 700 mg, 750 mg, 800 mg, 900 mg, 1000 mg, 1250 mg, 1500 mg, 1750 mg, 1800 mg, 1900 mg, 2 g, 2.1 g, 2.2 g, 2.3 g, 2.4 g, 2.5 g, 2.6 g, 2.7 g, 2.8 g, or 2.9 g).
- any size therebetween e.g., 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, 475 mg, 490 mg, 500 mg, 550 mg, 575 mg, 600 mg, 650 mg, 675 mg, 700 mg, 750 mg, 800 mg, 900 mg, 1000 mg, 1250 mg, 1500 mg, 1750 mg, 1800 mg, 1900 mg, 2
- a composition provided herein can be provided in the form of a gel cap, soft gelatin capsule (e.g., soft gel capsule), or hard gelatin capsule.
- a composition described herein can be encapsulated by a hard gel capsule.
- soft gel capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
- Soft gel capsule manufacturing methods are described in, e.g., U.S. Pat. No. 6,333,047.
- compositions provided herein can be formulated as capsules that can demonstrate improved shelf life, homogeneity, and product stability.
- Compositions can be designed to contain fillers such as beeswax, carnauba wax, and other polymeric media to mask any separation of formulations, e.g., in soft gel capsules.
- fillers such as beeswax, carnauba wax, and other polymeric media to mask any separation of formulations, e.g., in soft gel capsules.
- the addition of such fillers can require the use of larger capsules or an increase in dose to obtain therapeutic (e.g., effective) levels of active ingredients.
- a composition incorporating a small carboxylic acid ester can be more stable than a composition lacking a small carboxylic acid ester in that (1) the composition is miscible and (2) the composition does not separate into separate phases in less than 24 hours, or less than 1 week, or less than 1 month.
- a small carboxylic acid ester can be present in an amount of less than about 5% by weight of the composition, or less than about 2% by weight, or less than about 1% by weight, to stabilize (or to improve the stability of) a composition described herein.
- Particularly useful carboxylic acid esters include, without limitation, triethyl citrate, diethyl maleate, and diethyl L-tartrate.
- compositions provided herein can be designed to contain a surfactant that wets, solubilizes, and/or emulsifies lipophilic components such as sterol compounds (e.g., phytosterol compounds) and/or fatty acid compounds (e.g., fish oil components and ⁇ -3 fatty acids such as EPA or DHA).
- a surfactant is a food grade surfactant.
- a surfactant can be anionic, cationic, zwitterionic, or non-ionic.
- a surfactant can have a surface tension below 70 dyne/cm2, or below 40 dyne/cm2.
- a surfactant can have a hydrophilic/lipophilic balance of less than 20, or less than 10. See, e.g., Surfactants in Chemistry, J. Falbe, Ed., Springer-Verlag (1989), pp: 149-152.
- surfactants can be used in any combination or relative ratio.
- surfactants include, without limitation, alkanoylglycerides, monoacylglycerides, or monoglycerides (e.g., from rapeseed, canola, and cottonseed oils); propylene glycol monoesters (e.g., propylene glycol monostearate); lactoylesters; stearic acid; sodium stearoyl lactylate; ethoxylated alcohols; ethoxylated fatty esters and fatty esters; ethyoxylated glycerol esters; phosphorous organic derivatives such as dodecyl phosphonic acid, dodecyl phosphate, decylphosphonic acid, decyl phosphate, dioctylphosphate, myristearylphosphonic acid, lecithin and lecithin derivatives; sorbitan derivatives such as polyoxyethylene sorbitan monolaurate,
- Sorbitan derivatives and phosphorous organic derivatives, such as lecithin can be used as surfactants to increase stability of a composition, particularly a composition formulated as a soft gel cap or hard shell caplet, or to increase bioavailability of a sterol compound (e.g., a phytosterol compound) and/or a fatty acid compound (e.g., a ⁇ -3 fatty acid compound).
- a sterol compound e.g., a phytosterol compound
- a fatty acid compound e.g., a ⁇ -3 fatty acid compound
- a surfactant can be less than 10% by weight of the composition, or less than 5%, or less than 2%.
- Dietary supplement compositions according to the invention can be provided in any suitable dosage form, the selection and implementation of which will be apparent to those skilled in the art in view of the disclosure herein.
- dosage forms include: a liquid, a gel, a tablet, a capsule, a powder, a confectionary, a shake, a bar, and a supplemented food.
- suitable excipients, flavorings, colorants, and the like will be apparent to those skilled in the art in view of the disclosure herein.
Abstract
This document provides dietary supplements. For example, composition having a combination of ingredients useful in reducing cholesterol and improving overall cardiovascular health as well as methods for reducing cholesterol and improving overall cardiovascular health are provided.
Description
- This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Ser. No. 61/233,242, filed on Aug. 12, 2009, which is incorporated by reference in its entirety herein.
- 1. Technical Field
- This document relates to the field of dietary supplements. For example, this document relates to composition having a combination of ingredients useful in reducing cholesterol and improving overall cardiovascular health.
- 2. Background Information
- Cardiovascular disease (CVD) is a major cause of deaths and disabilities throughout the world. The risk of CVD is determined by several factors, such as a person's lifestyle, diet, and genetic background. While physicians have used various statin drugs, such as lovastatin, pravastatin, and simavastatin to reduce cholesterol levels, the impact of these prescription medications on the heart, liver, and muscles have raised safety concerns. In addition, the use of statins is mainly focused on reducing serum cholesterol levels, while CVD has multiple pathological mechanisms.
- A major factor in CVD is atherosclerosis, a process of accumulating plaques in major blood vessels. This disease is very hard to treat and almost impossible to reverse, but it is highly preventable. There are few risk factors responsible for atherosclerosis progression. One of the most important is high blood cholesterol. According to modern research the mechanism of arterial plaque formation includes free radical oxidation of LDL, the major cholesterol transporting complex in the blood. Another important aspect of atherosclerosis development is inflammation. Increased inflammatory background is not just a risk factor, it is an indicator of active plaque formation processes. Thus, a high level of inflammatory markers in the blood is believed to be a better predictor of cardiac events than high cholesterol.
- Given the grave consequences of CVD and the costs and risk associated with medical treatments, there is a need for nutritional interventions that are useful for preventing the occurrence and reoccurrence of these conditions.
- This document provides dietary supplements. For example, this document provides composition having a combination of ingredients useful in reducing cholesterol and improving overall cardiovascular health as well as methods for reducing cholesterol and improving overall cardiovascular health.
- One aspect of this document features a dietary supplement comprising, or consisting essentially of, (a) from about 400 mg to about 3000 mg phytosterols, (b) from about 110 mg to about 1000 mg omega-3 fatty acids, (c) from about 6 mg to about 60 mg coenzyme Q-10, (d) from about 6 mg to about 45 mg alpha lipoic acid, and (e) from about 2.5 mg to about 20 mg bromelain. In some cases, the dietary supplement can comprise, or consist essentially of, (a) from about 1400 mg to about 2800 mg phytosterols, (b) from about 300 mg to about 800 mg omega-3 fatty acids, (c) from about 20 mg to about 40 mg coenzyme Q-10, (d) from about 20 mg to about 36 mg alpha lipoic acid, and (e) from about 8 mg to about 15 mg bromelain. In some cases, the dietary supplement can comprise, or consist essentially of, (a) about 2000 mg phytosterols, (b) about 550 mg omega-3 fatty acids, (c) about 30 mg coenzyme Q-10, and (d) about 30 mg alpha lipoic acid.
- In some cases, a dietary supplement can comprise, or consist essentially of, (a) about 500 mg phytosterols; (b) about 250 mg omega-3 fatty acids; (c) about 7.5 mg coenzyme Q-10; and (d) about 7.5 mg alpha lipoic acid. In some cases, a dietary supplement can comprise, or consist essentially of, (a) from about 1000 mg to about 3000 mg phytosterols; (b) from about 500 mg to about 1500 mg omega-3 fatty acids; (c) from about 15 mg to about 45 mg coenzyme Q-10; (d) from about 15 mg to about 45 mg alpha lipoic acid; and (e) from about 2.5 mg to about 20 mg bromelain.
- Further provided herein is a method for improving cardiovascular heath in a mammal. In some cases, the method can include administering to the mammal a daily dosage of a dietary supplement, wherein the dietary supplement can include: (a) from about 1000 mg to about 3000 mg phytosterols; (b) from about 500 mg to about 1500 mg omega-3 fatty acids; (c) from about 15 mg to about 45 mg coenzyme Q-10; (d) from about 15 mg to about 45 mg alpha lipoic acid; and (e) from about 2.5 mg to about 20 mg bromelain.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
- In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present document. It will be obvious, however, to one skilled in the art that the subject matter provided herein may be practiced without these specific details. In other instances, well-known aspects of dietary supplements and the various compositions discussed herein have not been described in particular detail in order to avoid unnecessarily obscuring the subject matter provided herein.
- This document provides methods and compositions related to lowering blood cholesterol, reducing the inflammation background, and increasing the antioxidant potential of the blood. The methods and compositions are believed to slow down atherosclerosis development and lower the risk of cardiac events. In particular, the methods and compositions are believed to provide a variety of health benefits, including: helping reduce the risk of heart disease, helping support heart and blood vessel function, naturally helping reduce cholesterol levels for a healthier heart and life, supporting blood circulation, adding coenzyme Q-10 to offset reduced amounts during aging, and helping to regenerate antioxidants.
- For example, the document provides compositions (e.g. dietary supplements) containing a sterol compound, omega-3 fatty acids (EPA/DHA), coenzyme Q10, and α-lipoic acid.
- Also provided herein are methods of administering a daily dose of a dietary supplement as provided herein. In some cases, the dietary supplement can be formulated with amounts as provided herein. Administration can be provided as one or more compositions (e.g., tablets).
- Compositions provided herein can contain a sterol compound such as a phytosterol compound. In some cases, the sterol can be synthetic. The term “sterol” includes, without limitation, plant, animal, and synthetic sterols, sterol esters, stanols, and stanol esters. Plant sterols (and sterol esters) are naturally occurring substances present in the diet as minor components of vegetable oils, while plant stanols (and stanol esters) are hydrogenation compounds of the plant sterols.
- The cholesterol lowering effect of sterols is thought to be associated with their structural similarity.
- Sterols may compete with cholesterol for places in micelles—small fat particles which form during digestion in order to adsorb fat. Because of this, sterols may prevent absorption and re-absorption of cholesterol from the intestinal tract and thus can affect blood cholesterol levels.
- Sterols have been approved for safe use by the FDA and they have been safely used in studies lasting up to 18 months. A significant number of research studies have shown that sterols can reduce total cholesterol and LDL cholesterol levels.
- Sterol compounds (e.g., phytosterols and phytosterol esters) can be obtained commercially from a variety of sources, e.g., Cargill, Inc. (Minneapolis, Minn.), Loders and Croklaan (Channahon, Ill.), Cognis Nutrition and Health (La Grange, Ill.), Forbes Meditech (Vancouver, B.C. Canada), and ADM (Decatur, Ill.) and can demonstrate a range of sterol profiles. In addition, sterol compounds can be synthesized and/or obtained from natural sources such as soy oil, canola oil, or wheat germ oil as described elsewhere (see e.g. U.S. Pat. Nos. 6,411,206; 5,502,045; 6,087,353; and 4,897,224, each of which is incorporated herein by reference in its entirety).
- Suitable examples of phytosterol esters that can be used to prepare a composition provided herein include, without limitation, beta-sitosterol laurate ester, alpha-sitosterol laurate ester, gamma-sitosterol laurate ester, campesterol myristearate ester, stigmasterol oleate ester, campesterol stearate ester, beta-sitosterol oleate ester, beta-sitosterol palmitate ester, beta-sitosterol linoleate ester, alpha-sitosterol oleate ester, gamma-sitosterol oleate ester, beta-sitosterol myristearate ester, beta-sitosterol ricinoleate ester, campesterol laurate ester, campesterol ricinoleate ester, campesterol oleate ester, campesterol linoleate ester, stigmasterol linoleate ester, stigmasterol laurate ester, stigmasterol caprate ester, alpha-sitosterol stearate ester, gamma-sitosterol stearate ester, alpha-sitosterol myristearate ester, gamma-sitosterol palmitate ester, campesterol ricinoleate ester, stigmasterol ricinoleate ester, campesterol ricinoleate ester, beta-sitosterol, alpha-sitosterol, gamma-sitosterol, campesterol, stigmasterol, and stigmasterol stearate ester.
- In some embodiments, a sterol compound can be a phytostanol ester. Sterol compounds such as phytostanols and phytostanol esters can be obtained commercially from, e.g., Forbes Meditech (Vancouver, B.C. Canada), or can be readily synthesized. Alternatively, phytostanols and phytostanol esters can be obtained from natural sources such as soy oil, canola oil, or wheat germ oil as described elsewhere (see e.g. U.S. Pat. Nos. 6,411,206; 5,502,045; 6,087,353; and 4,897,224).
- Examples of phytostanol esters that can be used to make a composition provided herein include, without limitation, beta-sitostanol laurate ester, campestanol myristearate ester, stigmastanol oleate ester, campestanol stearate ester, beta-sitostanol oleate ester, beta-sitostanol palmitate ester, beta-sitostanol linoleate ester, beta-sitostanol myristearate ester, beta-sitostanol ricinoleate ester, campestanol laurate ester, campestanol ricinoleate ester, campestanol oleate ester, campestanol linoleate ester, stigmastanol linoleate ester, stigmastanol laurate ester, stigmastanol caprate ester, stigmastanol stearate ester, alpha-sitostanol laurate ester, gamma-sitostanol laurate ester, alpha-sitostanol oleate ester, gamma-sitostanol oleate ester, alpha-sitostanol stearate ester, gamma-sitostanol stearate ester, alpha-sitostanol myristearate ester, gamma-sitostanol palmitate ester, campestanol ricinoleate ester, stigmastanol ricinoleate ester, campestanol ricinoleate ester, beta-sitostanol, alpha-sitostanol, gamma-sitostanol, campestanol, and stigmastanol.
- A composition provided herein can contain any type of sterol compound such as a phytosterol, phytosterol ester, phytostanol, or phytostanol ester. In addition, a composition provided herein can contain any amount of sterol compounds (e.g., 10, 25, 50, 100, 200, 250, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 750, 800, or 900 mg). For example, between 35 to 95 percent (e.g., from 35 to 95 percent, from 50 to 95 percent, from 75 to 95 percent, from 85 to 95 percent, from 35 to 85 percent, from 35 to 75 percent, or from 35 to 55 percent) of a composition provided herein can contain sterol compounds. In some cases, a composition provided herein can be designed to contain multiple sterol compounds in any relative ratio (e.g., 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1). In certain cases, a composition provided herein can be a nutritional supplement with a label indicating that a suggested serving size includes greater than 1 g (e.g., about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 3.0, 3.5 g or more) of total sterol compounds per day.
- Typically, a composition provided herein can be designed to contain a phytosterol ester compound or mixtures thereof. In some cases, a composition provided herein can be designed to contain one or more phytosterol ester compounds in a total amount ranging from about 45% to about 95% by weight of the composition. In certain embodiments, one or more phytosterol ester compounds can be provided in a total amount from about 45% to about 60% by weight of the composition. In other embodiments, one or more phytosterol ester compounds can be provided in a total amount of about 70% to about 85% by weight of the composition.
- A composition provided herein can contain one or more phytosterol compounds. In certain embodiments, one or more phytosterols can be present in a total amount from about 1% to about 85% by weight of the composition. In certain compositions, one or more phytosterol compounds may be present in a total amount from about 1% to about 10% by weight of the composition. In other compositions, one or more phytosterols can be present in a total amount of from about 40% to about 55%, or from about 70% to about 85% by weight of the composition.
- In certain embodiments, a composition provided herein can contain one or more phytostanol ester compounds, e.g., in a total amount of from about 45% to about 95% by weight of the composition. In certain embodiments, one or more phytostanol ester compounds can be provided in a total amount of about 45% to about 60% by weight of the composition. In other embodiments, one or more phytostanol ester compounds can be provided in a total amount of about 70% to about 85% by weight of the composition.
- In certain compositions, one or more phytostanol compounds can be present in a total amount from about 1% to about 85% by weight of the composition. In other compositions, one or more phytostanols can be present in a total amount of from about 1% to about 10%, from about 40% to about 55%, or from about 70% to about 85% by weight of the composition.
- The compositions provided herein can contain one or more fatty acid compounds (e.g., ω-3 fatty acid compounds). Omega-3 fatty acids stimulate blood circulation, increase the breakdown of fibrin, a compound involved in clot and scar formation, and additionally have been shown to reduce blood pressure. There is strong scientific evidence that ω-3 fatty acids reduce blood triglyceride levels and regular intake reduces the risk of secondary and primary heart attack.
- Two common forms of omega-3 fatty acids are can generally be in a form generally known as eicosapentanoic acid (EPA) and derivatives thereof and docosahexanoic acid (DHA) and derivatives thereof.
- Fatty acid compounds such as ω-3 fatty acid compounds can be obtained from fish oils or vegetable oils, or synthesized. In some cases, fatty acid compounds such as ω-3 fatty acid compounds can be formulated in a composition as a fish oil or vegetable oil or mixture thereof. For example, a fish oil containing DHA, EPA, or both, can be used to make a composition provided herein. Fish oils are available commercially from BLT Berg Lipidtech AS, Clover Corporation, Denofa AS, Bioriginal Food and Science Corp., ProNova Biocare, BASF, and NutriScience Innovations LLC, and can demonstrate a range of ω-3 fatty acid profiles. In certain cases, a fish oil can contain about 11-14% DHA and about 16-19% EPA, and a total ω-3 fatty acid content of about 33-41%. For example, a fish oil can contain about 12% DHA and about 18% EPA. In other cases, a fish oil can contain about 30-33% EPA and about 20-22% DHA, and a total α-3 fatty acid content of about 50-67%. In other cases, a fish oil can contain about 50-55% DHA and about 5-10% EPA. In yet other cases, a fish oil can contain about 50-55% EPA and about 5-10% DHA. In other examples, a fish oil can contain at least 20% DHA and at least 25% EPA, and a total ω-3 fatty acid content of at least 60%, e.g., at least 65%. In yet other cases, a fish oil can contain about 5% EPA and about 25% DHA, and a total ω-3 fatty acid content of about 30%, e.g., about 35%.
- In addition to the use of a pure fish oil, a fish oil containing EPA and/or DHA (or derivatives thereof) can be modified by, e.g., the addition of purified EPA and/or DHA (or derivatives thereof) to result in a particular ratio or amount of EPA and/or DHA (or derivatives thereof). In other embodiments, purified EPA and/or DHA, or derivatives thereof, can be used to make a composition provided herein. In certain embodiments, a ratio of EPA to DHA, or derivatives thereof, can be from about 1:5 to about 5:1, or from about 1:2 to about 2:1, or from about 1.5:1 to about 1:1.5. For example, a fish oil can contain EPA and DHA at a ratio of about 1.5:1.
- Typically, a composition provided herein can contain a fish oil in a range of from about 10% to about 55% by weight of the composition, or from about 10% to about 30% by weight of the composition. In other embodiments, EPA and/or DHA, or derivatives thereof, can be used in purified form to make a composition provided herein. The combined amount of EPA and DHA (or derivatives thereof) can range from about 30% to about 55% by weight of the composition. In certain embodiments, the combined amount of EPA and DHA can range from about 20% to about 40% by weight of the composition. In other embodiments, the combined amount of EPA and DHA can range from about 12% to about 16% by weight of the composition.
- Fish oils, purified EPA, DHA, and derivatives thereof such as DHA and EPA, can be obtained commercially from, for example, Croda, Inc. (Parsippany, N.J.), Roche Vitamins Ltd. (Parsippany, N.J.), Martek (Boulder, Colo.), Maritex (Sortland, Norway), Seven Seas, Pronova (Lysker, Norway), and Loder Croklann Lipid Nutrition (Channahon, Ill.), and Cargill, Inc. (Minneapolis, Minn.).
- A composition provided herein can be a nutritional supplement. A nutritional supplement can include a label indicating that a suggested serving size includes at least 300 mg (e.g., about 300, 350, 400, 420, 450, 500, 500-600, 600-900, 1000, 1100, 1200, 900-1200, 1200-1500 mg, 1500 mg-2 g, 2 g-2.5 g, 2.5 g-3 g, or more) of total ω-3 fatty acids per day. One or more ω-3 fatty acids can be derived from one or more fish, purified ω-3 fatty acids, or mixtures thereof. In some embodiments, a nutritional supplement can include a label indicating that a suggested serving size includes at least 300 mg of DHA and EPA per day.
- The compositions provided herein can contain Coenzyme Q-10. Coenzyme Q-10 (also referred to herein as CoQ10), a powerful antioxidant, helps support heart and blood vessel functions and is involved in the process that produces cellular energy. All risk groups (of atherosclerosis) should preferably maintain a healthy blood level of CoQ10. This is important for people who are on statin (inhibitors of cholesterol biosynthesis) therapy.
- Coenzyme Q10 (CoQ10) is produced by the human body and is necessary for the basic functioning of cells. CoQ10 plays a key role in producing energy in the mitochondria, the part of a cell responsible for the production of energy in the form of ATP. It does so through the conversion of oxidized and reduced forms (ubiquinone-ubiquinol) of the coenzyme.
- The similar transformation play a very important antioxidant role: the major fat soluble, membrane antioxidant vitamin E is only effective in the presence of CoQ10 because of its cyclic regeneration.
- CoQ10 levels are reported to decrease with age and to be low in patients with some chronic diseases such as heart conditions, muscular dystrophies, Parkinson's disease, cancer, diabetes, and HIV/AIDS. People with heart failure have been found to have lower levels of CoQ10 in heart muscle cells. Some prescription drugs may also lower CoQ10 levels.
- CoQ10 (in appropriate form) is relatively bioavailable. The average plasma level in human is about 0.7-0.9 μg/mL. Desirable levels for people with elevated risk of heart disease is more than 1 μg/mL. Supplementation may increase the plasma level very quickly.
- CoQ10 can be included in an amount ranging from about 0.01% to about 2% by weight of the composition, or from about 0.1% to about 1% by weight.
- The compositions provided herein can contain α-Lipoic acid (LA), also known as thioctic acid, LA is an essential cofactor for several important enzyme complexes, it can directly scavenge (neutralize) physiologically relevant Reactive Oxygen and Nitrogen Species (ROS and RNS), it also can directly or indirectly regenerate the oxidized forms of other antioxidants such as Ascorbic acid, α-Tocopherol, and CoQ10.
- LA is a naturally occurring compound that is synthesized in small amounts by plants and animals, including humans. LA contains two thiol (sulfur) groups. The reduced form is known as dihydrolipoic acid (DHLA), while the oxidized form is known as LA.
- Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are highly reactive compounds with the potential to damage DNA, proteins and lipids (fats) in cell membranes. Both LA and DHLA can directly scavenge (neutralize) physiologically relevant ROS and RNS in the test tube. However, it is not clear whether LA acts directly to scavenge ROS and RNS in vivo. When an antioxidant scavenges a free radical, it becomes oxidized itself and is not able to scavenge additional ROS or RNS until it has been reduced. DHLA is a potent reducing agent with the capacity to reduce the oxidized forms of several important antioxidants, including vitamin C and glutathione. DHLA may also reduce the oxidized form of alpha-tocopherol (the alpha-tocopheroxyl radical) directly or indirectly, by reducing the oxidized form of vitamin C (dehydroascorbate), which is able to reduce the alpha-tocopheroxyl radical. Coenzyme Q10 is an important component of the mitochondrial electron transport chain that also has antioxidant activity. DHLA can also reduce oxidized forms of coenzyme Q10, which may also reduce the alpha-tocopheroxyl radical. Although DHLA has been found to regenerate oxidized antioxidants in the test tube, it is not known whether DHLA effectively regenerates other antioxidants under physiological conditions.
- In addition to antioxidant regeneration functions, LA has multiple health benefits. Glutathione is an important intracellular antioxidant that also plays a role in the detoxification and elimination of potential carcinogens and toxins. LA has been found to increase glutathione synthesis in cultured cells and in the tissues of aged animals fed LA.
- Compositions provided herein can contain bromelain. Generally, the bromelain is provided in an amount ranging from about 0.1% to about 5% by weight of the composition, or from about 0.5% to about 2.5% by weight of the composition. Bromelain is the generic name for a family of sulfhydryl-containing proteolytic enzymes obtained from the pineapple plant. A bromelain enzyme blend generally contains a sulfydryl proteolytic fraction, a peroxidase, an acid phosphatase, several protease inhibitors, and calcium.
- This document provides compositions that can include one or more of: sterols, omega-3 fatty acids, coenzyme Q-10, and alpha lipoic acid. In some cases, a dietary supplement composition provided herein can contain the amounts indicated in Table 1 below.
-
TABLE 1 Component Daily Dosage Phytosterols 2000 mg Omega-3 fatty acids 550 mg Coenzyme Q-10 30 mg Alpha lipoic acid 30 mg - In some cases, a dietary supplement composition provided herein can contain the amounts indicated in Table 2 below.
-
TABLE 2 Component Daily Dosage Phytosterols 2000 mg Omega-3 fatty acids 1000 mg Coenzyme Q-10 30 mg Alpha lipoic acid 30 mg - In another case, a daily dosage of the dietary supplement composition can contain the following:
- a) from about 400 mg to about 3000 mg phytosterols
- b) from about 110 mg to about 1000 mg omega-3 fatty acids;
- c) from about 6 mg to about 60 mg coenzyme Q-10;
- d) from about 6 mg to about 45 mg alpha lipoic acid; and
- e) from about 2.5 mg to about 20 mg bromelain.
- In still another case, a daily dosage of the dietary supplement composition can contain the following:
- a) from about 1400 mg to about 2800 mg phytosterols;
- b) from about 300 mg to about 800 mg omega-3 fatty acids;
- c) from about 20 mg to about 40 mg coenzyme Q-10;
- d) from about 20 mg to about 36 mg alpha lipoic acid; and
- e) from about 8 mg to about 15 mg bromelain.
- In some cases, a daily dosage of the dietary supplement composition can contain the following:
- a) from about 1000 mg to about 3000 mg phytosterols
- b) from about 500 mg to about 1500 mg omega-3 fatty acids;
- c) from about 15 mg to about 45 mg coenzyme Q-10;
- d) from about 15 mg to about 45 mg alpha lipoic acid; and
- e) from about 2.5 mg to about 20 mg bromelain.
- The phrase “daily dose” as used herein refers to the amount of active ingredient administered over a 24 hour period. A daily dose may be prepared and administered in the form of one or more tablets (e.g., two tablets, three tablets, four tablets, five tablets, and six tablets). In some cases, the one or more tablets can be administered in one or more dosages over the course of 24 hours (e.g., one dose, two doses, three doses, four doses, five doses, and six doses), wherein the one or more dosages do not exceed the total daily dose.
- In some cases, when a daily dose is prepared for administration as a single tablet per day, the tablet can contain the following:
- a) about 2000 mg phytosterols;
- b) about 1000 mg omega-3 fatty acids;
- c) about 30 mg coenzyme Q-10; and
- d) about 30 mg alpha lipoic acid.
- In other cases, when a daily dose is prepared for administration as two tablets per day, each tablet can contain the following:
- a) about 1000 mg phytosterols;
- b) about 500 mg omega-3 fatty acids;
- c) about 15 mg coenzyme Q-10; and
- d) about 15 mg alpha lipoic acid.
- In another case, when a daily dose is prepared for administration as four tablets per day, each tablet can contain the following:
- a) about 500 mg phytosterols;
- b) about 250 mg omega-3 fatty acids;
- c) about 7.5 mg coenzyme Q-10; and
- d) about 7.5 mg alpha lipoic acid.
- Compositions described herein can contain additional optional ingredients. For example, optional coloring and/or flavoring agents, e.g., to reduce the odor associated with fish oil and fish oil components, can be included. In addition, the compositions can contain a pharmaceutically acceptable carrier for in vivo administration to a mammal, including, without limitation, preservatives and other additives such as, for example, botanical extracts.
- Compositions provided herein can be formulated as nutritional supplements, e.g., as liquids or capsules for oral ingestion. Capsules can be hard-shell or soft gel capsules.
- The compositions provided herein can be ingested (e.g., orally or intragastrically). The route of administration can depend on a variety of factors, such as the health of the patient and the therapeutic goals. One method of administration is orally in the form of capsules at daily-recommended dosages. Capsules are provided in sizes that are acceptable for the consumer to swallow. For example, capsules can be in the range from about 250 mg to 3 g in size, or any size therebetween (e.g., 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, 475 mg, 490 mg, 500 mg, 550 mg, 575 mg, 600 mg, 650 mg, 675 mg, 700 mg, 750 mg, 800 mg, 900 mg, 1000 mg, 1250 mg, 1500 mg, 1750 mg, 1800 mg, 1900 mg, 2 g, 2.1 g, 2.2 g, 2.3 g, 2.4 g, 2.5 g, 2.6 g, 2.7 g, 2.8 g, or 2.9 g).
- A composition provided herein can be provided in the form of a gel cap, soft gelatin capsule (e.g., soft gel capsule), or hard gelatin capsule. For example, a composition described herein can be encapsulated by a hard gel capsule. For oral administration, soft gel capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. Soft gel capsule manufacturing methods are described in, e.g., U.S. Pat. No. 6,333,047.
- The compositions provided herein can be formulated as capsules that can demonstrate improved shelf life, homogeneity, and product stability. Compositions can be designed to contain fillers such as beeswax, carnauba wax, and other polymeric media to mask any separation of formulations, e.g., in soft gel capsules. The addition of such fillers can require the use of larger capsules or an increase in dose to obtain therapeutic (e.g., effective) levels of active ingredients.
- A composition incorporating a small carboxylic acid ester can be more stable than a composition lacking a small carboxylic acid ester in that (1) the composition is miscible and (2) the composition does not separate into separate phases in less than 24 hours, or less than 1 week, or less than 1 month. A small carboxylic acid ester can be present in an amount of less than about 5% by weight of the composition, or less than about 2% by weight, or less than about 1% by weight, to stabilize (or to improve the stability of) a composition described herein. Particularly useful carboxylic acid esters include, without limitation, triethyl citrate, diethyl maleate, and diethyl L-tartrate.
- The compositions provided herein can be designed to contain a surfactant that wets, solubilizes, and/or emulsifies lipophilic components such as sterol compounds (e.g., phytosterol compounds) and/or fatty acid compounds (e.g., fish oil components and ω-3 fatty acids such as EPA or DHA). Typically, a surfactant is a food grade surfactant. A surfactant can be anionic, cationic, zwitterionic, or non-ionic. In certain embodiments, a surfactant can have a surface tension below 70 dyne/cm2, or below 40 dyne/cm2. A surfactant can have a hydrophilic/lipophilic balance of less than 20, or less than 10. See, e.g., Surfactants in Chemistry, J. Falbe, Ed., Springer-Verlag (1989), pp: 149-152.
- One or more surfactants can be used in any combination or relative ratio. Examples of surfactants include, without limitation, alkanoylglycerides, monoacylglycerides, or monoglycerides (e.g., from rapeseed, canola, and cottonseed oils); propylene glycol monoesters (e.g., propylene glycol monostearate); lactoylesters; stearic acid; sodium stearoyl lactylate; ethoxylated alcohols; ethoxylated fatty esters and fatty esters; ethyoxylated glycerol esters; phosphorous organic derivatives such as dodecyl phosphonic acid, dodecyl phosphate, decylphosphonic acid, decyl phosphate, dioctylphosphate, myristearylphosphonic acid, lecithin and lecithin derivatives; sorbitan derivatives such as polyoxyethylene sorbitan monolaurate, sorbitan oleate, sorbitan laurate, sorbitan palmitate, sorbitan stearate, sorbitan myristearate, sorbitan ricinoleate, sorbitan linoleneate, and sorbitan linoleate; stearoyl-2-lactylates of sodium or calcium; sucrose and glucose esters and derivatives thereof; sulfosuccinates and derivatives; and mixtures of any of the above. Sorbitan derivatives and phosphorous organic derivatives, such as lecithin, can be used as surfactants to increase stability of a composition, particularly a composition formulated as a soft gel cap or hard shell caplet, or to increase bioavailability of a sterol compound (e.g., a phytosterol compound) and/or a fatty acid compound (e.g., a ω-3 fatty acid compound).
- Surfactants can be obtained commercially as described elsewhere (“McCutcheon's Emulsifiers and Detergents,” Int'l Ed. (2001), The Manufacturing Confectioner Publishing Co., NJ, USA). A surfactant can be less than 10% by weight of the composition, or less than 5%, or less than 2%.
- Dietary supplement compositions according to the invention can be provided in any suitable dosage form, the selection and implementation of which will be apparent to those skilled in the art in view of the disclosure herein. Examples of such dosage forms include: a liquid, a gel, a tablet, a capsule, a powder, a confectionary, a shake, a bar, and a supplemented food. The selection and use of suitable excipients, flavorings, colorants, and the like will be apparent to those skilled in the art in view of the disclosure herein.
- Further details on the use of sterols and fatty acid compounds in dietary supplements can be found U.S. Patent Publication No. 20050032757, entitled “Nutritional Supplements” and published Feb. 10, 2005, which is incorporated herein by reference in its entirety. All other references and patents referenced herein also expressly incorporated herein by reference in their entireties.
- It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (4)
1. A dietary supplement, comprising:
a) from about 400 mg to about 3000 mg phytosterols;
b) from about 110 mg to about 1000 mg omega-3 fatty acids;
c) from about 6 mg to about 60 mg coenzyme Q-10;
d) from about 6 mg to about 45 mg alpha lipoic acid; and
e) from about 2.5 mg to about 20 mg bromelain.
2. A dietary supplement, comprising:
a) about 500 mg phytosterols;
b) about 250 mg omega-3 fatty acids;
c) about 7.5 mg coenzyme Q-10; and
d) about 7.5 mg alpha lipoic acid.
3. A dietary supplement, comprising:
a) from about 1000 mg to about 3000 mg phytosterols
b) from about 500 mg to about 1500 mg omega-3 fatty acids;
c) from about 15 mg to about 45 mg coenzyme Q-10;
d) from about 15 mg to about 45 mg alpha lipoic acid; and
e) from about 2.5 mg to about 20 mg bromelain.
4. A method for improving cardiovascular heath in a mammal, said method comprising administering to said mammal a daily dosage of a dietary supplement comprising:
a) from about 1000 mg to about 3000 mg phytosterols
b) from about 500 mg to about 1500 mg omega-3 fatty acids;
c) from about 15 mg to about 45 mg coenzyme Q-10;
d) from about 15 mg to about 45 mg alpha lipoic acid; and
e) from about 2.5 mg to about 20 mg bromelain.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/854,944 US20110038848A1 (en) | 2009-08-12 | 2010-08-12 | Dietary supplement compositions for cardiovascular health |
US15/395,105 US11278553B2 (en) | 2009-08-12 | 2016-12-30 | Dietary supplement compositions for cardiovascular health |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23324209P | 2009-08-12 | 2009-08-12 | |
US12/854,944 US20110038848A1 (en) | 2009-08-12 | 2010-08-12 | Dietary supplement compositions for cardiovascular health |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/395,105 Continuation US11278553B2 (en) | 2009-08-12 | 2016-12-30 | Dietary supplement compositions for cardiovascular health |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110038848A1 true US20110038848A1 (en) | 2011-02-17 |
Family
ID=43588716
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/854,944 Abandoned US20110038848A1 (en) | 2009-08-12 | 2010-08-12 | Dietary supplement compositions for cardiovascular health |
US15/395,105 Active US11278553B2 (en) | 2009-08-12 | 2016-12-30 | Dietary supplement compositions for cardiovascular health |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/395,105 Active US11278553B2 (en) | 2009-08-12 | 2016-12-30 | Dietary supplement compositions for cardiovascular health |
Country Status (1)
Country | Link |
---|---|
US (2) | US20110038848A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016109856A1 (en) | 2015-01-02 | 2016-07-07 | Melaleuca, Inc. | Multi-supplement compositions |
US10137164B2 (en) | 2015-01-02 | 2018-11-27 | Melaleuca, Inc. | Dietary supplement compositions |
CN108904455A (en) * | 2018-07-20 | 2018-11-30 | 汤臣倍健股份有限公司 | A kind of preparation method of the tablet containing high dose grease ingredient |
US10576112B2 (en) | 2015-01-02 | 2020-03-03 | Melaleuca, Inc. | Bacterial compositions |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576284A (en) * | 1983-12-02 | 1986-03-18 | Warner-Lambert Company | Closing of filled capsules |
US4897224A (en) * | 1985-03-05 | 1990-01-30 | Morinaga Milk Industry Co., Ltd. | Method for producing ferulyl stanol derivatives |
US5502045A (en) * | 1991-05-03 | 1996-03-26 | Raision Tehtaat Oy Ab | Use of a stanol fatty acid ester for reducing serum cholesterol level |
US6087353A (en) * | 1998-05-15 | 2000-07-11 | Forbes Medi-Tech Inc. | Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like |
US6211206B1 (en) * | 1995-06-20 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US6333047B1 (en) * | 1997-05-09 | 2001-12-25 | Daiichi Kasei Co., Ltd. | Molded capsule superior in strength and stability and method for preparing same |
US20030203854A1 (en) * | 2002-04-23 | 2003-10-30 | Ivo Pischel | Composition for effecting serum cholesterol levels |
US20050032757A1 (en) * | 2003-08-06 | 2005-02-10 | Cho Suk H. | Nutritional supplements |
US6933291B2 (en) * | 2000-12-01 | 2005-08-23 | N.V. Nutricia | Cholesterol lowering supplement |
US7229651B2 (en) * | 1997-08-06 | 2007-06-12 | Melaleuca, Inc. | Dietary supplements containing natural ingredients |
US20090110674A1 (en) * | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000004887A2 (en) | 1998-07-20 | 2000-02-03 | Forbes Medi-Tech Inc. | Compositions comprising phytosterol, phytostanol or mixtures of both and omega-3 fatty acids or derivatives thereof and use of the composition in treating or preventing cardiovascular disease and other disorders |
-
2010
- 2010-08-12 US US12/854,944 patent/US20110038848A1/en not_active Abandoned
-
2016
- 2016-12-30 US US15/395,105 patent/US11278553B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576284A (en) * | 1983-12-02 | 1986-03-18 | Warner-Lambert Company | Closing of filled capsules |
US4897224A (en) * | 1985-03-05 | 1990-01-30 | Morinaga Milk Industry Co., Ltd. | Method for producing ferulyl stanol derivatives |
US5502045A (en) * | 1991-05-03 | 1996-03-26 | Raision Tehtaat Oy Ab | Use of a stanol fatty acid ester for reducing serum cholesterol level |
US6211206B1 (en) * | 1995-06-20 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US6333047B1 (en) * | 1997-05-09 | 2001-12-25 | Daiichi Kasei Co., Ltd. | Molded capsule superior in strength and stability and method for preparing same |
US7229651B2 (en) * | 1997-08-06 | 2007-06-12 | Melaleuca, Inc. | Dietary supplements containing natural ingredients |
US6087353A (en) * | 1998-05-15 | 2000-07-11 | Forbes Medi-Tech Inc. | Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like |
US6933291B2 (en) * | 2000-12-01 | 2005-08-23 | N.V. Nutricia | Cholesterol lowering supplement |
US20030203854A1 (en) * | 2002-04-23 | 2003-10-30 | Ivo Pischel | Composition for effecting serum cholesterol levels |
US20050032757A1 (en) * | 2003-08-06 | 2005-02-10 | Cho Suk H. | Nutritional supplements |
US20090110674A1 (en) * | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
Non-Patent Citations (4)
Title |
---|
Melaleuca, Phytomega FAQ, "Phytomega Heart Health Supplement", Melaleuca, (2008) available online at cdnus.melaleuca.com/PDF/BusinessCenter/Reference_Library/PIB/FAQ_Phytomega_enUs.pdf * |
Sabharwal et al, "Alpha-Lipoic acid and ascorbate prevent LDL oxidation and oxidant stress in endothelial cells" Molecular and Cellular Biochemistry, 2008, Vol 306 p 125-132. * |
Vitality for Life "ProvexCV: Cardio Vascular Protection" available via Google search on Sep 30, 2002, available online at content.melaleuca.com/wc/pdf/ProVexCV_REDO2.pdf * |
Vitality for life, "Phytomega" (2003), USA, available at content.melaleuca.com/wc/pdf/Phytomega_Info.pdf * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016109856A1 (en) | 2015-01-02 | 2016-07-07 | Melaleuca, Inc. | Multi-supplement compositions |
CN107404927A (en) * | 2015-01-02 | 2017-11-28 | 麦莱琉卡有限公司 | Multiple complementary goods composition |
US10137164B2 (en) | 2015-01-02 | 2018-11-27 | Melaleuca, Inc. | Dietary supplement compositions |
US10576112B2 (en) | 2015-01-02 | 2020-03-03 | Melaleuca, Inc. | Bacterial compositions |
US11207388B2 (en) | 2015-01-02 | 2021-12-28 | Melaleuca, Inc. | Multi-supplement compositions |
US11273195B2 (en) | 2015-01-02 | 2022-03-15 | Melaleuca, Inc. | Dietary supplement compositions |
EP3973972A1 (en) | 2015-01-02 | 2022-03-30 | Melaleuca, Inc. | Multi-supplement compositions |
US11433107B2 (en) | 2015-01-02 | 2022-09-06 | Melaleuca, Inc. | Bacterial compositions |
CN108904455A (en) * | 2018-07-20 | 2018-11-30 | 汤臣倍健股份有限公司 | A kind of preparation method of the tablet containing high dose grease ingredient |
Also Published As
Publication number | Publication date |
---|---|
US20170209463A1 (en) | 2017-07-27 |
US11278553B2 (en) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220118064A1 (en) | Multi-supplement compositions | |
US11207286B2 (en) | Self-emulsifying composition of w3 fatty acid | |
US6054128A (en) | Dietary supplements for the cardiovascular system | |
KR101590025B1 (en) | Composition for regulating lipid metabolism | |
US11278553B2 (en) | Dietary supplement compositions for cardiovascular health | |
Kapoor et al. | Coenzyme Q10-a novel molecule | |
US11490644B2 (en) | Co-Q10, krill oil and vitamin D | |
US7842679B2 (en) | Phospholipid derivatives of DHA and methods for treating respiratory failure using the same | |
TWI301065B (en) | Pharmaceutical compositions for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals | |
JP4896531B2 (en) | Pharmaceutical composition for increasing blood CoQ10 level | |
Ritzenthaler | Non-pharmaceutical Approaches To The Prevention and Treatment of Heart Disease: A Review Of Current Literature. | |
KR20060067988A (en) | The mixture composition containing the garlic, soy protein extract and taurine for the prevention of hyperlipidemia and visceral obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MELALEUCA, INC., IDAHO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RABOVSKY, ALEXANDER B.;IVIE, JEREMY;REEL/FRAME:025111/0781 Effective date: 20100916 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |